The Centre today said that 51 lakh (50,95,640) COVID-19 vaccine doses are in the pipeline and will be received by the States/UTs within the next 3 days. In its massive vaccination drive that began on January 16, the Centre has so far provided more than 20 crore vaccine doses (20,28,09,250) to States/UTs for free of cost. Of this, the total consumption, calculated based on average up to 14th May 2021, including wastages is 18,43,67,772 doses.
In a media release, the government of India also said that more than 1.84 crore COVID Vaccine doses (1,84,41,478) are still available with the States/UTs to be administered. "States with negative balance are showing more consumption (including wastage) than vaccine supplied as they have not reconciled the vaccine they have supplied to Armed Forces," it added.
As per the data, Maharashtra, Uttar Pradesh, West Bengal shall be receiving 50,000, 6,00,00 and 75,000 doses respectively. Nearly 24 states including UTs shall be receiving vaccine doses. Here is a look at the data which shows the consumption of the vaccines done by the states and those who will be receiving the vaccines.
Vaccination forms an integral component of the comprehensive strategy of Government of India of containment and management of the pandemic (including Test, Track, Treat and COVID Appropriate Behaviour). The Centre has been supporting the nationwide vaccination drive by providing COVID vaccines free of cost to states and UTs, in addition to several efforts to ramp up its production and supply, the ministry stated.
Implementation of the Liberalized and Accelerated Phase 3 Strategy of COVID-19 Vaccination has started from May 1 as part of which the government has opened up inoculation for all aged above 18.
Besides, vaccination with Bharat Biotech's COVID-19 vaccine - COVAXIN, has produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first identified in India and the United Kingdom, the vaccine manufacturer informed on Sunday.
As per an infographic, a modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G).
